Andrew J Mcmichael

List of Publications by Year
in descending order

191 papers	34,252 citations	6606 79 h-index	3576 181 g-index
200 all docs	200 docs citations	200 times ranked	20637 citing authors

#	Article	IF	Citations
1	HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature, 1998, 391, 795-799.	13.7	1,983
2	Common West African HLA antigens are associated with protection from severe malaria. Nature, 1991, 352, 595-600.	13.7	1,494
3	Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Medicine, 2002, 8, 379-385.	15.2	1,432
4	Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA. Science, 1998, 279, 2103-2106.	6.0	1,340
5	A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science, 2007, 317, 944-947.	6.0	1,136
6	Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Medicine, 1997, 3, 212-217.	15.2	1,096
7	Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature, 1991, 354, 453-459.	13.7	1,060
8	Cytotoxic T-Cell Immunity to Influenza. New England Journal of Medicine, 1983, 309, 13-17.	13.9	918
9	Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature, 2001, 410, 106-111.	13.7	910
10	Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nature Medicine, 2012, 18, 274-280.	15.2	882
11	HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function. Journal of Experimental Medicine, 2000, 192, 63-76.	4.2	820
12	The immune response during acute HIV-1 infection: clues for vaccine development. Nature Reviews Immunology, 2010, 10, 11-23.	10.6	707
13	Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature, 1992, 360, 434-439.	13.7	638
14	Rapid Effector Function in CD8+ Memory T Cells. Journal of Experimental Medicine, 1997, 186, 859-865.	4.2	626
15	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1253-1272.	4.2	562
16	Surface Expression of HLA-E, an Inhibitor of Natural Killer Cells, Enhanced by Human Cytomegalovirus gpUL40. Science, 2000, 287, 1031-1033.	6.0	554
17	Cellular immune responses to HIV. Nature, 2001, 410, 980-987.	13.7	550
18	HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature, 1988, 336, 484-487.	13.7	471

#	Article	IF	Citations
19	Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nature Medicine, 1996, 2, 906-911.	15.2	469
20	The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. European Journal of Immunology, 1997, 27, 1164-1169.	1.6	442
21	Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature, 1994, 369, 403-407.	13.7	438
22	Crystal structure of the complex between human CD8Î±Î± and HLA-A2. Nature, 1997, 387, 630-634.	13.7	428
23	Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27â€"Restricted Cytotoxic T Lymphocyte Responses. Journal of Experimental Medicine, 2001, 193, 375-386.	4.2	424
24	Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature, 1987, 326, 881-882.	13.7	420
25	Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature, 1990, 345, 449-452.	13.7	379
26	HLA-E is expressed on trophoblast and interacts with CD94â€‰/â€‰NKG2 receptors on decidual NK cells. European Journal of Immunology, 2000, 30, 1623-1631.	1.6	379
27	Common Genetic Variation and the Control of HIV-1 in Humans. PLoS Genetics, 2009, 5, e1000791.	1.5	377
28	Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. Journal of Clinical Investigation, 2008, 118, 3478-90.	3.9	373
29	HIV-1-Specific Mucosal CD8+ Lymphocyte Responses in the Cervix of HIV-1-Resistant Prostitutes in Nairobi. Journal of Immunology, 2000, 164, 1602-1611.	0.4	361
30	Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature, 1995, 375, 606-611.	13.7	342
31	A human lymphocyte-associated antigen involved in cell-mediated lympholysis. European Journal of Immunology, 1983, 13, 202-208.	1.6	315
32	ESCAPE OF HUMAN IMMUNODEFICIENCY VIRUS FROM IMMUNE CONTROL. Annual Review of Immunology, 1997, 15, 271-296.	9.5	315
33	Escape from the Dominant HLA-B27-Restricted Cytotoxic T-Lymphocyte Response in Gag Is Associated with a Dramatic Reduction in Human Immunodeficiency Virus Type 1 Replication. Journal of Virology, 2007, 81, 12382-12393.	1.5	299
34	A structural basis for immunodominant human T cell receptor recognition. Nature Immunology, 2003, 4, 657-663.	7.0	290
35	Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen. Journal of Virology, 1999, 73, 7524-7532.	1.5	288
36	A New Look at T Cells. Journal of Experimental Medicine, 1998, 187, 1367-1371.	4.2	265

#	Article	IF	Citations
37	Broadly targeted CD8 ⁺ T cell responses restricted by major histocompatibility complex E. Science, 2016, 351, 714-720.	6.0	260
38	Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing. PLoS ONE, 2010, 5, e12303.	1.1	259
39	TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Current Biology, 1998, 8, 1-10.	1.8	258
40	HIV VACCINES. Annual Review of Immunology, 2006, 24, 227-255.	9.5	257
41	Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen. Journal of Immunology, 2000, 164, 4968-4978.	0.4	247
42	Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine. PLoS ONE, 2007, 2, e984.	1.1	247
43	HIV vaccines 1983â€“2003. Nature Medicine, 2003, 9, 874-880.	15.2	240
44	Induction of Fas Ligand Expression by HIV Involves the Interaction of Nef with the T Cell Receptor Î¶ Chain. Journal of Experimental Medicine, 1999, 189, 1489-1496.	4.2	231
45	Natural T Cellâ€“mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1422-1431.	2.5	229
46	Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8 + T-Cell Epitopes. Journal of Virology, 2006, 80, 4717-4728.	1.5	220
47	Functions of nonclassical MHC and non-MHC-encoded class I molecules. Current Opinion in Immunology, 1999, 11, 100-108.	2.4	207
48	A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. Journal of General Virology, 2004, 85, 911-919.	1.3	206
49	Evasion of Cytotoxic T Lymphocyte (CTL) Responses by Nef-dependent Induction of Fas Ligand (CD95L) Expression on Simian Immunodeficiency Virusâ€“infected Cells. Journal of Experimental Medicine, 1997, 186, 7-16.	4.2	199
50	Characterization of the CD4+ T Cell Response to Epstein-Barr Virus during Primary and Persistent Infection. Journal of Experimental Medicine, 2003, 198, 903-911.	4.2	199
51	Structural Features Impose Tight Peptide Binding Specificity in the Nonclassical MHC Molecule HLA-E. Molecular Cell, 1998, 1, 531-541.	4.5	190
52	Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.. Nature Medicine, 2000, 6, 951-955.	15.2	190
53	Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. Journal of Clinical Investigation, 2001, 107, 341-349.	3.9	190
54	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Molecular Therapy, 2014, 22, 464-475.	3.7	188

#	Article	IF	Citations
55	MEDICINE: Enhanced: The Need for a Global HIV Vaccine Enterprise. Science, 2003, 300, 2036-2039.	6.0	186
56	Immune responses in HIV-exposed seronegatives: have they repelled the virus?. Current Opinion in Immunology, 1995, 7, 448-455.	2.4	183
57	Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nature Immunology, 2009, 10, 636-646.	7.0	170
58	T Cell Cross-Reactivity and Conformational Changes during TCR Engagement. Journal of Experimental Medicine, 2004, 200, 1455-1466.	4.2	159
59	Bound Water Structure and Polymorphic Amino Acids Act Together to Allow the Binding of Different Peptides to MHC Class I HLA-B53. Immunity, 1996, 4, 215-228.	6.6	155
60	The T-Cell Response to HIV. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007054-a007054.	2.9	155
61	Oligoclonal Expansions of CD8+ T Cells in Chronic HIV Infection Are Antigen Specific. Journal of Experimental Medicine, 1998, 188, 785-790.	4.2	153
62	HIV-Host Interactions: Implications for Vaccine Design. Cell Host and Microbe, 2016, 19, 292-303.	5.1	143
63	Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection. Journal of Virology, 2011, 85, 10518-10528.	1.5	141
64	Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. Aids, 2000, 14, 225-233.	1.0	140
65	Antagonist HIV-1 Gag Peptides Induce Structural Changes in HLA B8. Journal of Experimental Medicine, 1996, 184, 2279-2286.	4.2	136
66	T Cell Responses and Viral Escape. Cell, 1998, 93, 673-676.	13.5	127
67	Immune perturbations in HIV-1â€“infected individuals who make broadly neutralizing antibodies. Science Immunology, 2016, 1, aag0851.	5.6	120
68	Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. Journal of General Virology, 2007, 88, 1-12.	1.3	118
69	An immunodominant NP105â€“113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nature Immunology, 2022, 23, 50-61.	7.0	110
70	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Molecular Therapy, 2016, 24, 832-842.	3.7	107
71	BirA Enzyme: Production and Application in the Study of Membrane Receptorâ€“Ligand Interactions by Site-Specific Biotinylation. Analytical Biochemistry, 1999, 266, 9-15.	1.1	104
72	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. Blood, 1999, 93, 1506-1510.	0.6	104

#	Article	IF	Citations
73	HIV-specific Cytotoxic T Cells from Long-Term Survivors Select a Unique T Cell Receptor. Journal of Experimental Medicine, 2004, 200, 1547-1557.	4.2	103
74	Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable. Nature Communications, 2016, 7, 11660.	5.8	103
75	Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. European Journal of Immunology, 2005, 35, 341-351.	1.6	99
76	Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine, 1999, 17, 589-596.	1.7	97
77	Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nature Immunology, 2006, 7, 179-189.	7.0	91
78	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. PLoS Pathogens, 2011, 7, e1001273.	2.1	90
79	Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunology Letters, 1999, 66, 177-181.	1.1	88
80	Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nature Immunology, 2012, 13, 423-427.	7.0	84
81	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nature Communications, 2018, 9, 1928.	5.8	83
82	Elevation of Intact and Proteolytic Fragments of Acute Phase Proteins Constitutes the Earliest Systemic Antiviral Response in HIV-1 Infection. PLoS Pathogens, 2010, 6, e1000893.	2.1	80
83	Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.. Journal of General Virology, 1998, 79, 83-90.	1.3	79
84	The role of HLA-B27 in spondyloarthritis. Immunogenetics, 1999, 50, 220-227.	1.2	78
85	Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors. Journal of Experimental Medicine, 2014, 211, 1273-1280.	4.2	76
86	The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. European Journal of Immunology, 1995, 25, 1927-1931.	1.6	75
87	Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. European Journal of Immunology, 1995, 25, 3270-3276.	1.6	74
88	CD4+ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4+ Cells. Cell Reports, 2020, 30, 137-152.e5.	2.9	74
89	Vaccines that stimulate T cell immunity to HIV-1: the next step. Nature Immunology, 2014, 15, 319-322.	7.0	72
90	A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. Journal of General Virology, 2002, 83, 75-80.	1.3	72

#	Article	IF	Citations
91	Peptide selection by class I molecules of the major histocompatibility complex. Current Biology, 1993, 3, 854-866.	1.8	71
92	Design and Validation of an Enzyme-Linked Immunospot Assay for Use in Clinical Trials of Candidate HIV Vaccines. AIDS Research and Human Retroviruses, 2002, 18, 611-618.	0.5	70
93	Ex Vivo Phenotype and Frequency of Influenza Virus-Specific CD4 Memory T Cells. Journal of Virology, 2004, 78, 7284-7287.	1.5	67
94	High Levels of Virus-Specific CD4⁺ T Cells Predict Severe Pandemic Influenza A Virus Infection. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1292-1297.	2.5	64
95	Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. II. Blocking studies with monoclonal antibodies to HLA determinants. European Journal of Immunology, 1981, 11, 694-699.	1.6	63
96	HIV/AIDS: HLA Leaves Its Footprints on HIV. Science, 2002, 296, 1410-1411.	6.0	62
97	Protective Efficacy of Serially Up-Ranked Subdominant CD8+ T Cell Epitopes against Virus Challenges. PLoS Pathogens, 2011, 7, e1002041.	2.1	62
98	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight, 2017, 2, e91868.	2.3	59
99	An Early HIV Mutation within an HLA-B*57-Restricted T Cell Epitope Abrogates Binding to the Killer Inhibitory Receptor 3DL1. Journal of Virology, 2011, 85, 5415-5422.	1.5	57
100	Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nature Communications, 2018, 9, 3137.	5.8	57
101	Effects of monoclonal antibodies to the a and Î² chains of the human lymphocyte function-associated (H-LFA-1) antigen on T lymphocyte functions. European Journal of Immunology, 1985, 15, 888-892.	1.6	54
102	Cytotoxic Tâ€“cell abundance and virus load in human immunodeficiency virus type 1 and human Tâ€“cell leukaemia virus type 1. Proceedings of the Royal Society B: Biological Sciences, 2001, 268, 1215-1221.	1.2	54
103	Requirement of the Proteasome for the Trimming of Signal Peptide-derived Epitopes Presented by the Nonclassical Major Histocompatibility Complex Class I Molecule HLA-E. Journal of Biological Chemistry, 2003, 278, 33747-33752.	1.6	54
104	The Role of MHC-E in T Cell Immunity Is Conserved among Humans, Rhesus Macaques, and Cynomolgus Macaques. Journal of Immunology, 2018, 200, 49-60.	0.4	54
105	Cytotoxic T Lymphocytes Specific for Influenza Virus. Current Topics in Microbiology and Immunology, 1994, 189, 75-91.	0.7	53
106	Class I cross-restricted T cells reveal low responder allele due to processing of viral antigen. Nature, 1989, 337, 653-655.	13.7	52
107	Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine, 2008, 26, 6671-6677.	1.7	50
108	Identification of T cell receptor recognition residues for a viral peptide presented by HLA B27. European Journal of Immunology, 1994, 24, 2357-2363.	1.6	49

#	Article	IF	Citations
109	Casting a wider net: Immunosurveillance by nonclassical MHC molecules. PLoS Pathogens, 2019, 15, e1007567.	2.1	49
110	Contribution of proteasome-catalyzed peptide<i>cis</i>-splicing to viral targeting by CD8⁺T cells in HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24748-24759.	3.3	48
111	Epitope specificity of clonally expanded populations of CD8+ T cells found within the joints of patients with inflammatory arthritis. Arthritis and Rheumatism, 2001, 44, 2038-2045.	6.7	40
112	Lack of Truncated IFITM3 Transcripts in Cells Homozygous for the rs12252-C Variant That is Associated With Severe Influenza Infection. Journal of Infectious Diseases, 2018, 217, 257-262.	1.9	40
113	Homocysteine modification of HLA antigens and its immunological consequences. European Journal of Immunology, 1996, 26, 1443-1450.	1.6	39
114	Characterization of the HLA-A2.2 subtype: T cell evidence for further heterogeneity. Immunogenetics, 1985, 21, 11-23.	1.2	38
115	Mechanisms of Protection Induced by Attenuated Simian Immunodeficiency Virus II. Lymphocyte Depletion Does Not Abrogate Protection. AIDS Research and Human Retroviruses, 1998, 14, 1187-1198.	0.5	38
116	Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals. Journal of Virology, 2011, 85, 3507-3516.	1.5	38
117	Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection. PLoS Pathogens, 2016, 12, e1005805.	2.1	36
118	Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. Aids, 2012, 26, 275-284.	1.0	35
119	HLA-Eâ€“restricted, Gag-specific CD8 ⁺ T cells can suppress HIV-1 infection, offering vaccine opportunities. Science Immunology, 2021, 6, .	5.6	35
120	The original sin of killer T cells. Nature, 1998, 394, 421-422.	13.7	34
121	Is an HIV vaccine possible?. Nature Medicine, 1999, 5, 612-614.	15.2	34
122	Production and crystallization of MHC class I B allele single peptide complexes. FEBS Letters, 1996, 383, 119-123.	1.3	33
123	An antigen processing polymorphism revealed by HLA-B8-restricted cytotoxic T lymphocytes which does not correlate with TAP gene polymorphism. European Journal of Immunology, 1993, 23, 1999-2004.	1.6	32
124	Production, crystallization, and preliminary Xâ€ray analysis of the human MHC class Ib molecule HLAâ€E. Protein Science, 1998, 7, 1264-1266.	3.1	32
125	Combined structural and immunological refinement of HIV-1 HLA-B8-restricted cytotoxic T lymphocyte epitopes. European Journal of Immunology, 1997, 27, 1515-1521.	1.6	30
126	The arrival of HLA class II tetramers. Journal of Clinical Investigation, 1999, 104, 1669-1670.	3.9	29

#	Article	IF	Citations
127	First-Class Control of HIV-1. Science, 2010, 330, 1488-1490.	6.0	27
128	The Antiviral Efficacy of HIV-Specific CD8+ T-Cells to a Conserved Epitope Is Heavily Dependent on the Infecting HIV-1 Isolate. PLoS Pathogens, 2011, 7, e1001341.	2.1	26
129	Differential processing of influenza nucleoprotein in human and mouse cells. European Journal of Immunology, 1998, 28, 625-635.	1.6	25
130	The dynamics of the cellular immune response to HIV infection: implications for vaccination. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 1007-1011.	1.8	24
131	A review of vaccines for HIV prevention. Journal of Gene Medicine, 2003, 5, 3-10.	1.4	24
132	Induction of long-lasting multi-specific CD8+T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. European Journal of Immunology, 2006, 36, 2574-2584.	1.6	24
133	Detailed and atypical HLAâ€•E peptide binding motifs revealed by a novel peptide exchange binding assay. European Journal of Immunology, 2020, 50, 2075-2091.	1.6	24
134	Increased detection of proliferating, polyfunctional, HIVâ€•1â€•specific T cells in DNAâ€•modified vaccinia virus Ankaraâ€•vaccinated human volunteers by cultured IFNâ€•Î³ ELISPOT assay. European Journal of Immunology, 2009, 39, 975-985.	1.6	23
135	Evidence for the persistence of monoclonal expansions of CD8+ T cells following primary simian immunodeficiency virus infection. European Journal of Immunology, 1998, 28, 1172-1180.	1.6	22
136	Novel HIVâ€•1 clade B candidate vaccines designed for HLAâ€•B[*]5101⁺ patients protected mice against chimaeric ecotropic HIVâ€•1 challenge. European Journal of Immunology, 2009, 39, 1831-1840.	1.6	22
137	Identification of novel HIV-1-derived HLA-E-binding peptides. Immunology Letters, 2018, 202, 65-72.	1.1	21
138	New templates for HIV-1 antibody-based vaccine design. F1000 Biology Reports, 2010, 2, 60.	4.0	20
139	HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. Molecular Therapy, 2017, 25, 494-503.	3.7	19
140	Importance of a conserved TCR J Î±-encoded tyrosine for T cell recognition of an HLA B27/ peptide complex. European Journal of Immunology, 1998, 28, 2704-2713.	1.6	18
141	Lysis of allogeneic human lymphocytes by nonspecifically activated T-like cells. European Journal of Immunology, 1982, 12, 1002-1005.	1.6	17
142	Selection of T cell receptor variable gene-encoded amino acids on the third binding site loop: a factor influencing variable chain selection in a T cell response. European Journal of Immunology, 1995, 25, 1529-1534.	1.6	17
143	Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo. Clinical Infectious Diseases, 2015, 61, 120-128.	2.9	17
144	Capturing the antigen landscape: HLA-E, CD1 and MR1. Current Opinion in Immunology, 2019, 59, 121-129.	2.4	17

#	Article	IF	Citations
145	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. Blood, 1999, 93, 1506-1510.	0.6	16
146	Maintenance of MHC polymorphism. Nature, 1992, 355, 403-403.	13.7	15
147	Triple bypass: complicated paths to HIV escape. Journal of Experimental Medicine, 2007, 204, 2785-2788.	4.2	15
148	Natural selection at work on the surface of virus-infected cells. Science, 1993, 260, 1771-1772.	6.0	14
149	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. Communications Biology, 2022, 5, 271.	2.0	14
150	A cross-species functional interaction between the murine major histocompatibility complex class I Î±3 domain and human CD8 revealed by peptide-specific cytotoxic T lymphocytes. European Journal of Immunology, 1992, 22, 1643-1646.	1.6	13
151	Expression and function of HLA-B27 in lipid-linked form: Implications for cytotoxic T lymphocyte-induced apoptosis signal transduction. European Journal of Immunology, 1993, 23, 653-658.	1.6	12
152	Effects of Retroviral Protease Inhibitors on Proteasome Function and Processing of HIV-Derived MHC Class I-Restricted Cytotoxic T Lymphocyte Epitopes. AIDS Research and Human Retroviruses, 2001, 17, 1063-1066.	0.5	12
153	AIDS/HIV: Finding Footprints Among the Trees. Science, 2007, 315, 1505-1507.	6.0	12
154	Preexisting compensatory amino acids compromise fitness costs of a HIV-1ÂT cell escape mutation. Retrovirology, 2014, 11, 101.	0.9	12
155	Unusual antigen presentation offers new insight into HIV vaccine design. Current Opinion in Immunology, 2017, 46, 75-81.	2.4	12
156	Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029124.	2.3	12
157	Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques. PLoS ONE, 2014, 9, e114709.	1.1	11
158	Why the long latent period?. Nature, 1990, 348, 388-388.	13.7	10
159	Cytotoxic T Lymphocytes: Specificity, Surveillance, and Escape. Advances in Cancer Research, 1992, 59, 227-244.	1.9	10
160	T cell receptor usage in infectious disease. Seminars in Immunopathology, 1999, 21, 37-54.	4.0	10
161	Role of class I molecules of the major histocompatibility complex in cytotoxic T-cell function in health and disease. Seminars in Immunopathology, 1992, 14, 1-16.	4.0	9
162	Cytotoxic T lymphocytes and immune surveillance. Cancer Surveys, 1992, 13, 5-21.	1.5	9

#	Article	IF	Citations
163	HLA B27: a disease-associated immune response gene. Research in Immunology, 1991, 142, 475-482.	0.9	8
164	Reversion and T Cell Escape Mutations Compensate the Fitness Loss of a CD8+ T Cell Escape Mutant in Their Cognate Transmitted/Founder Virus. PLoS ONE, 2014, 9, e102734.	1.1	8
165	Primary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes. Cell Reports, 2022, 39, 110959.	2.9	8
166	Nosing ahead in the cold war. Nature, 1990, 344, 16-16.	13.7	7
167	Engagement of a T cell receptor by major histocompatibility complex irrespective of peptide. European Journal of Immunology, 1997, 27, 879-885.	1.6	7
168	Legacy of the influenza pandemic 1918: The host TÂcell response. Biomedical Journal, 2018, 41, 242-248.	1.4	6
169	Interrogating the recognition landscape of a conserved HIV-specific TCR reveals distinct bacterial peptide cross-reactivity. ELife, 2020, 9, .	2.8	6
170	Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. Journal of Clinical Investigation, 2021, 131, .	3.9	6
171	How viruses hide from T cells. Trends in Microbiology, 1997, 5, 211-212.	3.5	5
172	Influenza vaccines: mTOR inhibition surprisingly leads to protection. Nature Immunology, 2013, 14, 1205-1207.	7.0	5
173	Introduction: Presentation of viral antigens to cytotoxic T cells. Seminars in Virology, 1996, 7, 1-2.	4.1	4
174	Topological perspective on HIV escape. Science, 2019, 364, 438-439.	6.0	4
175	GIMAP6 regulates autophagy, immune competence, and inflammation in mice and humans. Journal of Experimental Medicine, 2022, 219, .	4.2	4
176	From influenza to HIVâ€"and back?. Nature Immunology, 2007, 8, 1149-1151.	7.0	3
177	Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. Journal of Virology, 2018, 92, .	1.5	3
178	The Importance of Cellular Immune Response to HIV: Implications for Antibody Production and Vaccine Design. DNA and Cell Biology, 2021, , .	0.9	3
179	Tamarin compatibility. Nature, 1990, 346, 17-17.	13.7	2
180	A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology, 2017, 14, 46.	0.9	2

#	Article	IF	Citations
181	T cell receptor usage in infectious disease. Seminars in Immunopathology, 1999, 21, 37-54.	4.0	2
182	Recognition of viral antigens at the cell surface. Cancer Surveys, 1995, 22, 51-62.	1.5	2
183	Simplification of twoâ€dimensional gel patterns of HLA class II antigens. Tissue Antigens, 1986, 28, 72-83.	1.0	1
184	HIV-1 Vaccines: Letâ€™s Get Physical. Immunity, 2013, 38, 410-413.	6.6	1
185	Ita Askonas and her influence in the field of antigen presentation. Current Opinion in Immunology, 2014, 26, 111-114.	2.4	1
186	Effects Of A Monoclonal Antibody To Human Platelet Glycoprotein I On Platelet - Von Willebrand Factor Subendothelium Interactions. Thrombosis and Haemostasis, 1981, 46, 0297.	1.8	0
187	Immune Escape in Hiv Infection. Clinical Science, 1995, 88, 31P-31P.	0.0	0
188	Identification and Characterisation of Derp1-Specific CD8+ T Cells in the Peripheral Blood of Atopic Individuals. Clinical Science, 2002, 103, 2P-2P.	0.0	0
189	The use of tetramers in the quantitative analysis of T-cell responses. Methods in Microbiology, 2002, , 125-156.	0.4	0
190	Brigitte Alice Askonas. 1 April 1923â€"9 January 2013. Biographical Memoirs of Fellows of the Royal Society, 2018, 65, 31-45.	0.1	0
191	Gut microbiota induce local and systemic CD4 T cell responses in healthy individuals that are altered in inflammatory bowel diseases. Zeitschrift Fur Gastroenterologie, 2017, 55, .	0.2	0